• 首页期刊简介编委会刊物订阅专栏专刊电子刊广告合作联系我们English
引用本文:潘轶斌,包丽芳,陈杭,金烈,张向阳,华崇俊.不同剂量瑞舒伐他汀对急性冠脉综合征患者血NF-κB,sICAM-1表达的影响[J].中国现代应用药学,2011,28(6):572-575.
PAN Yibin,BAO Lifang,CHEN Hang,JIN Lie,ZHANG Xiangyang,HUA Chongjun.Effect of Different Doses of Rosuvastatin on Blood NF-κB and sICAM-1 in Patients with Acute Coronary Syndrome[J].Chin J Mod Appl Pharm(中国现代应用药学),2011,28(6):572-575.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2342次   下载 2325 本文二维码信息
码上扫一扫!
分享到: 微信 更多
不同剂量瑞舒伐他汀对急性冠脉综合征患者血NF-κB,sICAM-1表达的影响
潘轶斌, 包丽芳, 陈杭, 金烈, 张向阳, 华崇俊
金华市中心医院,浙江 金华 321001
摘要:
目的 探讨不同剂量的瑞舒伐他汀对急性冠脉综合征(ACS)患者血核因子-κB(NF-κB)、可溶性细胞间黏附因子(sICAM-1)表达的影响。方法 ACS患者随机分为瑞舒伐他汀10 mg组和20 mg组,另设健康对照组。治疗前及治疗后检测血NF-κB,sICAM-1及血脂等指标,进行治疗前后比较及组间比较。结果 ACS患者血NF-κB,sICAM-1水平较健康对照组显著升高(P<0.01),治疗4周后,瑞舒伐他汀10,20 mg组血NF-κB,sICAM-1活性下降,治疗前后有显著性差异。治疗后瑞舒伐他汀20 mg组比10 mg组血NF-κB,sICAM-1水平下降更显著(P<0.05)。结论 瑞舒伐他汀能有效降低ACS患者血NF-κB,sICAM-1水平,且大剂量作用更明显。
关键词:  瑞舒伐他汀  急性冠脉综合征  NF-κB  sICAM-1
DOI:
分类号:
基金项目:浙江省金华市科技局科研项目(2009-3-026)
Effect of Different Doses of Rosuvastatin on Blood NF-κB and sICAM-1 in Patients with Acute Coronary Syndrome
PAN Yibin, BAO Lifang, CHEN Hang, JIN Lie, ZHANG Xiangyang, HUA Chongjun
Jinhua Municipal Central Hospital, Jinhua 321001, China
Abstract:
OBJECTIVE To investigate the effect of different doses of rosuvastatin with acute coronary syndrome (ACS) patients on blood nuclear factor of kappa-B(NF-κB) and soluble intercellular adhesion molecule-1(sICAM-1) expression. METHODS ACS patients were randomized into rosuvastatin 10 mg group and 20 mg group. And forty healthy people were set as control group. Levels of blood NF-κB and sICAM-1 and blood lipids were measured between before treatment and after treatment. RESULTS Levels of blood NF-κB and sICAM-1 in ACS patients were significantly higher than healthy control group(P<0.01). After 4 weeks’ treatment, levels of blood NF-κB and sICAM-1 were decreased in rosuvastatin 10 mg group and 20 mg group. After treatment, levels of blood NF-κB and sICAM-1 were decreased more significantly in rosuvastatin 20 mg group than 10 mg group(P<0.05). CONCLUSION Rosuvastatin can reduce the levels of blood NF-κB and sICAM-1 in ACS patients, and high dose group is more evident.
Key words:  rosuvastatin  acute coronary syndrom  NF-κB  sICAM-1
扫一扫关注本刊微信